23andMe, the consumer genetic-testing pioneer, filed for bankruptcy protection, according to Reuters, after years of declining demand for its consumer kits, a significant data breach and a long struggle to build a business beyond the one-time test. Founder Anne Wojcicki resigned as chief executive as part of the restructuring.

The collapse is the clearest cautionary tale in consumer health technology. The product worked, the brand was strong and the initial demand was large, and none of that produced a durable business, because a genetic test is a purchase a consumer makes once and the company never built the recurring revenue that would replace it.

The recurring-revenue question

Every one-time-purchase consumer business eventually faces the same question: what does the customer buy next? 23andMe's answers, a health subscription and a drug-discovery business, were both late and both unsuccessful, and the company arrived at bankruptcy with a large customer base and no second product. The lesson is the one every consumer health founder now carries: a single test is not a business, and the second product has to be designed before the first one ships.